 ROCKVILLE, Md., Sept. 30, 2021 GLOBE NEWSWIRE -- OpGen, Inc. Nasdaq: OPGN, OpGen, a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has initiated the clinical trial for its Unyvero Urinary Tract Infection UTI Panel, which allows testing for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens. 